There are many elements at play as we have jumped in to the deep end of this pool on this. Some highlights of our thinking...

• We can currently collect (cost is the only limiting factor) sufficient biological data (terabytes needed) to be useful (DNA, biomarker profiles in blood and CSF)
• We are watching as costs for sequencing come down so we can activate on the largest population possible
  
• Unfortunately we can't correlate big data on the biology side with the limited, small data available on the clinical side (clinical scales such as UPDRS aren't nearly sensitive enough)
• We are evaluating the over 200 tracking devices commercially available to understand which will be most relevant for measuring PD patient activities. Such devices could collect big clinical data objectively (which is our goal) but need to validated as predictive tools
  
• Our recently formed data science team is working with elite technology partners to harness these possibilities across all of our significant data sets.
  

Debi